---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-07T17:05:05.859128'
end_time: '2026-09-07T17:25:59.541152'
duration_seconds: 1253.68
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Cornelia de Lange Syndrome 5
  mondo_id: MONDO:0010471
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
reference_validation:
  total_references: 18
  verified: 18
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 18
  on_topic: 9
  validator_version: 0.2.1
term_validation:
  total_terms: 51
  verified: 48
  not_found: 0
  obsolete: 1
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 8
  labels_matching: 0
  labels_mismatched: 7
  mislabelled_terms:
  - term_id: HP:0000574
    reported_labels:
    - characteristic across CdLS
    ontology_label: Thick eyebrow
  - term_id: HP:0000463
    reported_labels:
    - PMID 30614194
    ontology_label: Anteverted nares
  - term_id: HP:0000219
    reported_labels:
    - PMID 30614194
    ontology_label: Thin upper lip vermilion
  - term_id: HP:0000252
    reported_labels:
    - PMID 30614194
    ontology_label: Microcephaly
  - term_id: HP:0000717
    reported_labels:
    - significantly elevated vs comparison syndromes
    ontology_label: Autism
  - term_id: HP:0000739
    reported_labels:
    - common, persistent; intolerance of uncertainty a driver
    ontology_label: Anxiety
  - term_id: HP:0001250
    reported_labels:
    - subset
    ontology_label: Seizure
  labels_variant: 1
  obsolete_terms:
  - term_id: GO:0016575
    ontology_label: obsolete histone deacetylation
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Cornelia_de_Lange_Syndrome_5-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Cornelia_de_Lange_Syndrome_5-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Cornelia de Lange Syndrome 5
- **MONDO ID:** MONDO:0010471 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Cornelia de Lange Syndrome 5** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Cornelia de Lange Syndrome 5 (CdLS5, HDAC8-related) — Comprehensive Disease Report

**MONDO:0010471 · OMIM #300882 · Orphanet ORPHA:199 (CdLS group) · Gene: HDAC8 (Xq13.1)**

*Evidence source key: [H] human clinical/genetic; [M] model organism; [V] in vitro/biochemical; [C] computational/epigenomic. PMIDs cited throughout.*

---

## 1. Disease Information

**Overview.** Cornelia de Lange syndrome type 5 (CdLS5) is the X-linked form of Cornelia de Lange syndrome caused by loss-of-function variants in *HDAC8*, the gene encoding histone deacetylase 8, the enzyme that deacetylates the cohesin subunit SMC3. CdLS is a multisystem congenital malformation and neurodevelopmental disorder characterized by distinctive facial features, growth restriction (pre- and postnatal), intellectual disability, upper-limb anomalies, hirsutism/hypertrichosis, and involvement of the cardiac, gastrointestinal, genitourinary and other systems [H, PMID 29995837; 30614194]. CdLS is a "cohesinopathy" and, more broadly, a **disorder of transcriptional regulation (DTR)** [H, PMID 37377026]. HDAC8-related CdLS is frequently **non-classic/atypical**, and in many patients the clinical diagnosis was not suspected before genomic testing [H, PMID 24403048].

**Key identifiers.**
- MONDO: **MONDO:0010471** (Cornelia de Lange syndrome 5)
- OMIM phenotype: **#300882**; OMIM gene *HDAC8*: **300269**
- Orphanet: **ORPHA:199** (Cornelia de Lange syndrome, umbrella)
- Gene: **HDAC8**, HGNC:13315, NCBI Gene 55869, Ensembl ENSG00000147099, UniProt Q9BY41; cytoband **Xq13.1**
- ICD-10: **Q87.1** (congenital malformation syndromes predominantly associated with short stature); ICD-11: **LD2F.1Y**/typically coded under multiple-anomaly syndromes; MeSH: **D003635** (De Lange Syndrome)

**Synonyms/alternative names.** CdLS5; HDAC8-related Cornelia de Lange syndrome; X-linked Cornelia de Lange syndrome; Cornelia de Lange syndrome due to HDAC8 deficiency; historically overlapping terms: Brachmann–de Lange syndrome. "Wilson–Turner-like" X-linked ID has been noted for some HDAC8 variants in the differential.

**Data provenance.** This report is compiled from **aggregated disease-level resources** (OMIM, Orphanet, HPO, consensus statements) and **published patient cohorts** (e.g., 38-patient HDAC8 cohort [PMID 24403048]; 716-proband CdLS cohort [PMID 37377026]); not from individual EHR data.

---

## 2. Etiology

**Primary cause — genetic.** Hemizygous (males) or heterozygous (females) loss-of-function variants in *HDAC8* [H, PMID 24403048; 22885700]. HDAC8 is the vertebrate SMC3 deacetylase; CdLS-causing variants abolish enzymatic activity ("all cause a loss of enzymatic function") [H/V, PMID 24403048].

**Genetic risk factors.**
- *Causal variants:* predominantly **missense** and largely **de novo**; also nonsense, frameshift, splice, and deletions [H, PMID 24403048].
- *Modifier of expressivity in females:* pattern of **X-chromosome inactivation (XCI)**. Skewed XCI silencing the mutant allele attenuates phenotype; random/unfavorable XCI increases severity [H, PMID 24403048; 26671848].
- *Broader locus heterogeneity:* other CdLS genes (NIPBL, SMC1A, SMC3, RAD21, BRD4, ANKRD11) cause overlapping phenotypes; genetic background may modify.

**Environmental risk factors.** None established. CdLS is a monogenic Mendelian disorder; no confirmed toxic, infectious, dietary, or occupational cause. **Male sex** is a risk factor for greater severity in HDAC8-CdLS (hemizygosity, no XCI buffering) [H, PMID 24403048]. **Family history** relevant when a carrier mother is mosaic.

**Protective factors.** The principal "protective" mechanism is **favorable (skewed) X-inactivation** in heterozygous females, which can render carriers mildly affected or clinically unaffected [H, PMID 26671848]. No dietary/lifestyle protective factors are known. gnomAD constraint (HDAC8 highly intolerant to LoF) argues against benign LoF variation.

**Gene–environment interactions.** Not established; disease is essentially fully genetically determined. The main "gene–gene/epigenetic" interaction is XCI × mutant allele.

---

## 3. Phenotypes

HDAC8-CdLS overlaps classic CdLS but is often milder and has discriminating features. Frequencies below are drawn from CdLS-spectrum and HDAC8 cohorts [PMID 24403048; 30614194; 29995837]; HDAC8-specific frequencies are smaller-N.

**Craniofacial (near-universal; congenital).**
- Synophrys / arched eyebrows — HP:0000664 / HP:0000574 (characteristic across CdLS) [PMID 30614194]
- Short nose with anteverted nares, depressed bridge — HP:0003196 / HP:0000463 [PMID 30614194]
- Long philtrum, thin upper vermilion — HP:0000343 / HP:0000219 [PMID 30614194]
- Micrognathia — HP:0000347; low-set/posteriorly rotated ears
- **HDAC8-discriminating:** delayed anterior fontanelle closure (HP:0001476), **ocular hypertelorism (HP:0000316)**, hooding of eyelids, broader nose, **dental anomalies (HP:0000164)** [H, PMID 24403048]. *"often displays delayed anterior fontanelle closure, ocular hypertelorism, hooding of the eyelids, a broader nose and dental anomalies, which may be useful discriminating features"* [PMID 24403048].

**Growth (congenital/childhood, chronic).** Prenatal and postnatal growth restriction — HP:0001511 / HP:0001510; microcephaly (often postnatal) — HP:0000252 [PMID 30614194]. Severity generally milder in HDAC8 than NIPBL.

**Neurodevelopment (childhood, lifelong).** Intellectual disability — HP:0001249; global developmental delay — HP:0001263; speech delay — HP:0000750. HDAC8 cases trend milder cognitively than NIPBL but ID is typical.

**Neurobehavioral/psychiatric (childhood → adult; persistent).**
- Autism spectrum features — HP:0000717 (significantly elevated vs comparison syndromes) [H, PMID 23937369]; ASD criteria may increase over time [PMID 30941551]
- Anxiety — HP:0000739 (common, persistent; intolerance of uncertainty a driver) [PMID 36199025; 40878447]
- Self-injurious behavior — HP:0100716; stereotypies — HP:0000733
- Catatonia-like attenuated behavior in ~30.3% of CdLS [PMID 29536582]

**Limb (congenital).** Upper-limb reduction defects (oligodactyly, absent forearm) — HP:0009821/HP:0002984 are **characteristic of severe NIPBL CdLS but typically ABSENT or mild in HDAC8-CdLS** [PMID 24403048; 30158690]. Small hands/feet, 5th-finger clinodactyly (HP:0004209) may occur.

**Other systems.** Hirsutism/hypertrichosis — HP:0001007; congenital heart defects — HP:0001627 (e.g., septal defects, pulmonary stenosis); gastro-esophageal reflux and GI dysmotility — HP:0002020; cryptorchidism/genital anomalies — HP:0000028; hearing loss — HP:0000365; ptosis — HP:0000508; myopia/ophthalmologic issues; seizures — HP:0001250 (subset). Male hemizygotes more severely affected [PMID 24403048].

**Quality-of-life impact.** Substantial: lifelong intellectual disability, communication limits, anxiety, self-injury, GI symptoms, and feeding difficulty impair adaptive functioning and caregiver burden [PMID 36199025; 29536582]. Disease-specific/formal QoL instrument data (EQ-5D/SF-36) are limited for CdLS5 specifically — **not available at HDAC8 subtype resolution**.

---

## 4. Genetic / Molecular Information

**Causal gene.** *HDAC8* (HGNC:13315; OMIM 300269), Xq13.1, encoding a class I zinc-dependent histone/lysine deacetylase; physiological substrate for the CdLS mechanism is **cohesin subunit SMC3 (acetyl-K105/K106)** [H/V, PMID 22885700].

**Pathogenic variants.**
- *Types:* predominantly **missense** (clustered around catalytic residues/active site), plus nonsense, frameshift, splice-site, and intragenic/whole-gene deletions [H, PMID 24403048]. Recurrent examples reported include p.His180Arg, p.Gly304 region, p.Thr311Met, and catalytic-domain substitutions (variant-level detail curated in ClinVar/HGMD).
- *Classification (ACMG/AMP):* pathogenic/likely pathogenic for LoF and functionally validated missense; some VUS resolved by enzymatic assay or DNA-methylation episignature.
- *Allele frequency:* essentially **absent from population databases** (gnomAD) — consistent with a highly constrained, disease-causing gene.
- *Origin:* **germline**, mostly **de novo**; **maternal mosaicism** documented (unaffected mother mosaic → two affected sibs) [H, PMID 26671848]. HDAC8 somatic mutations occur in cancers but are unrelated to CdLS.
- *Functional consequence:* **loss of function / loss of enzymatic (deacetylase) activity** [H/V, PMID 24403048].

**Modifier genes / factors.** X-inactivation pattern is the dominant modifier in females [PMID 26671848]. NIPBL expression level correlates with severity across CdLS broadly [PMID 27125329]. No specific trans-modifier gene proven for HDAC8.

**Epigenetic information.** CdLS displays a reproducible genome-wide **DNA-methylation "episignature"** usable diagnostically; it can confirm diagnosis in mutation-negative patients and reclassify VUS, though sensitivity is heterogeneous across CdLS cases [C/H, PMID 38751117; 37872275]. Mechanistically, HDAC8 loss alters SMC3 acetylation and cohesin-dependent chromatin architecture/transcription [V, PMID 22885700].

**Chromosomal abnormalities.** CdLS5 is a single-gene disorder; large Xq13 deletions encompassing *HDAC8* can cause it and are detectable by CMA. Otherwise no characteristic karyotypic change.

---

## 5. Environmental Information
**Environmental factors:** none established. **Lifestyle factors:** none causal (monogenic disorder). **Infectious agents:** not applicable. (Environmental contribution is essentially nil; disease is genetically determined.)

---

## 6. Mechanism / Pathophysiology

### Causal chain (initiating lesion → clinical manifestation)
1. A loss-of-function *HDAC8* variant **results in** loss of HDAC8 lysine-deacetylase activity [H/V, PMID 24403048].
2. Loss of HDAC8 activity **leads to** failure to deacetylate SMC3 (acetyl-K105/K106) during mitotic exit **→ increased/retained SMC3 acetylation** [V, PMID 22885700].
3. Retained-acetyl SMC3 **results in** inefficient dissolution of the "used" cohesin complex released from chromatin (prophase and anaphase) and its improper recycling/reloading [V, PMID 22885700].
4. This **leads to** decreased occupancy at cohesin binding sites genome-wide **→ altered chromatin architecture and gene transcription** (a pattern shared with NIPBL-mutant CdLS) [V, PMID 22885700].
5. Dysregulated developmental transcription **results in** abnormal patterning/differentiation of multiple lineages, notably **cranial neural crest** — *(branch, demonstrated in mouse):* HDAC8 loss de-represses homeobox factors **Otx2 and Lhx1** in cranial neural crest, **leading to** skull/craniofacial malformation [M, PMID 19605684].
6. Multilineage transcriptional dysregulation during embryogenesis **results in** the CdLS phenotype: craniofacial dysmorphism, growth restriction, CNS/neurodevelopmental and behavioral abnormalities, limb, cardiac, and GI anomalies [H, PMID 29995837].
7. *(Female branch)* Skewed X-inactivation silencing the mutant *HDAC8* allele **attenuates** the phenotype; hemizygous males lack this buffering and are **more severely affected** [H, PMID 24403048; 26671848].

*Note on inference:* Steps 1–4 are biochemically demonstrated in human cells; step 5 (Otx2/Lhx1) is demonstrated in mouse neural crest and inferred to underlie human craniofacial features; step 6 is the clinical–molecular correlation.

### Detail by category
- **Molecular pathways:** cohesin cycle / sister-chromatid cohesion establishment–dissolution; cohesin-mediated chromatin looping and enhancer–promoter regulation (Reactome "Cohesin Loading onto Chromatin," "Establishment of Sister Chromatid Cohesion"). Downstream developmental TF networks (Otx2, Lhx1). Not a classic signaling cascade (Wnt/MAPK) primarily, though cohesin regulates many such loci.
- **Cellular processes:** GO:0016575 histone deacetylation; GO:0007062 sister chromatid cohesion; GO:0006325 chromatin organization; GO:0006351 transcription; cell-fate specification/patterning; cranial neural crest migration/differentiation. Increased apoptosis of neural crest in Hdac8-null skull [M, PMID 19605684].
- **Protein dysfunction:** loss of catalytic deacetylase activity (Zn2+-dependent hydrolase, InterPro/Pfam PF00850 Hist_deacetyl; PDB structures of HDAC8 available). Missense variants disrupt catalysis/substrate binding → LoF [V, PMID 24403048].
- **Biochemical abnormality:** enzyme deficiency — SMC3-lysine deacetylase (HDAC8) [V, PMID 22885700].
- **Epigenetic changes:** aberrant SMC3 acetylation; altered histone deacetylation of neural-crest TF loci; reproducible blood DNA-methylation episignature [PMID 22885700; 38751117].
- **Immune/metabolic involvement:** not central; no primary immunodeficiency/metabolic defect characteristic of CdLS5.
- **Transcriptomics:** CdLS cell lines (NIPBL or HDAC8 mutant) share a consistent altered transcription profile with reduced cohesin site occupancy [V, PMID 22885700].
- **Cell types (CL) / anatomy (UBERON):** CL:0000333 cranial neural crest cell; UBERON:0003129 skull; UBERON:0001890 forebrain.

---

## 7. Anatomical Structures Affected

- **Organ/system level (primary):** craniofacial skeleton/skull (UBERON:0003129), central nervous system/brain (UBERON:0000955), musculoskeletal/limbs (upper limb UBERON:0002102). **Secondary/associated:** heart (UBERON:0000948), gastrointestinal tract incl. esophagus (UBERON:0001043)/gut, genitourinary tract (UBERON:0000079), ears/auditory system (UBERON:0001690), eyes (UBERON:0000970), skin/hair (hypertrichosis).
- **Body systems:** nervous, craniofacial/skeletal, cardiovascular, digestive, genitourinary, integumentary, sensory (auditory/visual), endocrine (growth).
- **Tissue/cell level:** connective/skeletal (cranial bones), nervous tissue; key developmental population = **cranial neural crest cells (CL:0000333)** [M, PMID 19605684].
- **Subcellular (GO cellular component):** GO:0005634 nucleus; GO:0000785 chromatin; GO:0008278 cohesin complex; GO:0005737 cytoplasm (HDAC8 also cytoplasmic).
- **Localization/lateralization:** malformations are generally **bilateral/symmetric** (craniofacial midline and paired structures); limb involvement, when present in the broader spectrum, can be asymmetric.

---

## 8. Temporal Development

- **Onset:** **congenital** — malformations arise in embryogenesis; growth restriction detectable prenatally; dysmorphism recognizable at birth [H, PMID 29995837]. Onset pattern: chronic/static malformation with developmental unfolding.
- **Progression:** Non-progressive at the malformation level; **lifelong/chronic** course. Neurobehavioral features (autism traits, anxiety, catatonia-like attenuation) can **emerge or intensify across childhood into adulthood** [H, PMID 30941551; 29536582]. Adaptive ability tends to be stable with some receptive-language gains [PMID 30941551].
- **Patterns:** No remission (structural/genetic). **Critical period:** early embryonic neural-crest/organogenesis window sets the malformation; postnatally, early developmental/behavioral intervention is the actionable window.

---

## 9. Inheritance and Population

- **Epidemiology:** CdLS (all genes) estimated incidence/prevalence **~1/10,000–1/30,000** [H, PMID 32800026]. HDAC8 accounts for a **minority (~4–5%)** of CdLS; CdLS5 is correspondingly rarer. Precise CdLS5 prevalence: **not separately established**.
- **Inheritance:** **X-linked** (Xq13.1). De novo in most; can be inherited from a carrier/mosaic mother [PMID 24403048; 26671848].
- **Penetrance/expressivity:** Highly **variable expressivity**; in females penetrance/severity is modulated by **X-inactivation** (can be near-nonpenetrant with fully skewed favorable XCI) [PMID 26671848]. Males: essentially penetrant, more severe.
- **Genetic anticipation:** not applicable (not a repeat-expansion disorder).
- **Germline/somatic mosaicism:** documented **maternal mosaicism** with sibling recurrence [PMID 26671848]; relevant to recurrence-risk counseling.
- **Founder effects/consanguinity/carrier frequency:** no founder effect; consanguinity not relevant (X-linked, mostly de novo); carrier frequency negligible in general population (gnomAD LoF depleted).
- **Population demographics:** No ethnic predilection; CdLS occurs across global populations with consistent core features [H, PMID 30614194]. **Sex ratio:** both sexes affected; **males more severely affected**, females often milder/atypical [PMID 24403048]. Age distribution: present from birth through adulthood.

---

## 10. Diagnostics

- **Clinical criteria:** **2018 first international consensus** provides diagnostic criteria for **classic and non-classic CdLS** and a cardinal/suggestive feature scoring approach; recommends molecular confirmation [H, PMID 29995837]. Facial-analysis technology aids recognition across populations (sensitivity ≥95%, specificity ≥91%) [PMID 30614194].
- **Genetic testing (recommended, definitive):**
  - **Multigene NGS panel / WES / WGS** covering the seven CdLS/DTR genes incl. *HDAC8* — first-line; HDAC8 sequencing is "indispensable" in CdLS workup [H, PMID 26671848]. WGS adds detection of structural/deep-intronic variants.
  - **Single-gene *HDAC8* sequencing** when HDAC8 phenotype suspected.
  - **Chromosomal microarray (CMA)** to detect Xq13 deletions/CNVs.
  - **Deep/mosaicism-aware sequencing of multiple tissues** (buccal, fibroblasts) because somatic/parental mosaicism is common in CdLS [PMID 26671848].
  - **X-inactivation assay** in females to interpret expressivity [PMID 24403048].
- **Omics-based diagnostics:** **DNA-methylation episignature** as an orthogonal classifier to confirm mutation-negative CdLS and reclassify VUS [C, PMID 38751117; caution on sensitivity per PMID 37872275]. Functional **SMC3-deacetylation/enzyme assays** can validate missense VUS [V, PMID 24403048].
- **Supportive clinical tests:** echocardiography (CHD), hearing and ophthalmologic evaluation, GI/reflux workup, renal ultrasound, growth monitoring, developmental/behavioral assessment (per consensus surveillance) [PMID 29995837].
- **Differential diagnosis:** classic NIPBL-CdLS and other cohesinopathy genes (SMC1A, SMC3, RAD21); CdLS-like DTRs (ANKRD11/KBG, EP300, AFF4/CHOPS, TAF1, BRD4); Warsaw breakage syndrome (DDX11), Roberts syndrome (ESCO2), fetal alcohol spectrum, Coffin–Siris, Rubinstein–Taybi [H, PMID 31721174; 36703504].
- **Screening:** No population newborn screening (not applicable). **Cascade/carrier and prenatal testing** offered once a familial variant is known; prenatal ultrasound may show IUGR, limb/heart anomalies.

---

## 11. Outcome / Prognosis

- **Survival/life expectancy:** Many individuals survive into adulthood, particularly milder (incl. many HDAC8) cases; life expectancy is influenced by complications (severe CHD, GI/aspiration, infections). Formal CdLS5-specific survival statistics: **not established**. Hemizygous males (more severe) have poorer prognosis than mildly affected skewed-XCI females [PMID 24403048].
- **Morbidity/function:** Lifelong intellectual disability and behavioral morbidity (anxiety, ASD, self-injury, catatonia-like features) dominate disability burden [PMID 36199025; 29536582]. Growth failure, feeding/GI problems, hearing/vision deficits contribute.
- **Complications:** GERD and GI dysmotility, aspiration, recurrent infections, congenital heart disease, seizures, behavioral crises/self-injury.
- **Recovery potential:** Malformations are static; developmental and behavioral outcomes are improvable with early intervention/therapy; no cure.
- **Prognostic factors:** genotype/gene (HDAC8 milder than NIPBL), **sex and X-inactivation pattern**, severity of CHD/GI disease, degree of ID. No validated molecular prognostic biomarker beyond gene/variant and XCI [PMID 24403048; 27125329].

---

## 12. Treatment

No disease-modifying/curative therapy exists; management is **multidisciplinary and supportive**, per the 2018 consensus [H, PMID 29995837].

- **Supportive/medical (NCIT: C15277 Supportive Care):**
  - **GI:** anti-reflux medical therapy (proton-pump inhibitors — NCIT C29708; H2 blockers), nutritional support, fundoplication/gastrostomy for severe GERD/feeding failure.
  - **Cardiac:** surgical/medical management of congenital heart defects.
  - **ENT/audiology:** hearing aids, myringotomy tubes for otitis; ophthalmology for ptosis/refractive error.
  - **Growth/endocrine:** nutritional optimization; growth monitoring.
  - **Neurology:** anti-seizure medication if epilepsy.
- **Neurobehavioral/psychiatric (NCIT C15313 Psychosocial/Behavioral therapy; C265 Pharmacotherapy):** behavioral therapy for self-injury/ASD; SSRIs (e.g., sertraline — NCIT C47727) for anxiety/OCD-like symptoms; treat pain/occult GI sources of behavioral change; address intolerance of uncertainty in anxiety interventions [PMID 40878447; 36199025].
- **Surgical/interventional (NCIT C15329 Surgery):** cardiac repair, fundoplication/gastrostomy, orchidopexy for cryptorchidism, cleft/orthodontic and other reconstructive procedures as indicated.
- **Rehabilitative:** physical, occupational, and speech/language therapy; special education; early developmental intervention.
- **Advanced/experimental therapeutics:** **None approved.** No gene, cell, RNA, or targeted therapy in clinical use for CdLS5. HDAC-modulation strategies are conceptual/preclinical only; no CdLS-specific trials identified. Pharmacogenomics: no CdLS5-specific PGx guidance.
- **Treatment strategy:** individualized, guided by the consensus care/surveillance pathway; genotype-informed counseling but not yet genotype-targeted drug therapy [PMID 29995837].

---

## 13. Prevention

- **Primary prevention:** Not possible (mostly de novo genetic disorder). Prevention centers on **reproductive counseling** for families with a known variant.
- **Secondary prevention:** Early molecular diagnosis → structured **surveillance** (cardiac, GI, hearing, vision, growth, behavioral) to detect and treat complications early [PMID 29995837].
- **Tertiary prevention:** Aggressive management of GERD/aspiration, CHD, and behavioral/self-injury to prevent morbidity.
- **Genetic screening/counseling:** **genetic counseling** (X-linked risks, de novo vs mosaic recurrence), **prenatal testing / PGT** when a familial variant is known; test/counsel potentially mosaic mothers given documented sibling recurrence [PMID 26671848]. **NSGC/ACMG** counseling frameworks apply.
- **Immunization/public-health/environmental measures:** not applicable beyond routine pediatric care.

---

## 14. Other Species / Natural Disease

- **Taxonomy/orthologs:** *HDAC8* is conserved across vertebrates. Mouse *Hdac8* (NCBI Gene 70315; NCBI Taxon 10090); also conserved in rat, zebrafish. Cohesin/SMC3 machinery conserved from yeast (Hos1 is the yeast SMC3 deacetylase analog) to humans [PMID 22885700].
- **Natural disease in other species:** No well-characterized naturally occurring HDAC8-CdLS in companion/wild animals reported in OMIA; **not applicable/none documented**. Veterinary relevance: none established.
- **Comparative biology:** The cohesin acetylation cycle and neural-crest role of Hdac8 are evolutionarily conserved, underpinning cross-species disease modeling [PMID 22885700; 19605684].
- **Transmission/zoonosis:** not applicable (genetic disorder).

---

## 15. Model Organisms

- **Mouse (*Mus musculus*, NCBI Taxon 10090) — primary model [M, PMID 19605684]:**
  - *Global Hdac8 knockout:* perinatal lethality due to **skull instability** — models the craniofacial malformation.
  - *Conditional (cranial neural crest–specific, e.g., Wnt1-Cre) knockout:* **phenocopies** the skull defect, localizing pathogenesis to cranial neural crest.
  - *Mechanistic readout:* HDAC8 represses homeobox TFs **Otx2 and Lhx1**; loss de-represses them → aberrant skull patterning; increased neural-crest apoptosis.
  - *Recapitulation:* strong for craniofacial/skull patterning; *limitations:* global KO perinatal lethality limits study of postnatal neurobehavioral phenotypes; does not capture X-inactivation mosaicism of human females.
- **Zebrafish (*Danio rerio*) / cohesinopathy models:** cohesin (nipbl, esco2, rad21) models reproduce craniofacial and developmental gene-expression phenotypes, supporting the transcriptional-dysregulation mechanism shared with HDAC8 [M, PMID 29084713].
- **In vitro / cellular models:** patient-derived lymphoblastoid/fibroblast lines showing increased SMC3 acetylation, reduced cohesin occupancy, and altered transcription [V, PMID 22885700]; recombinant HDAC8 enzymatic assays to test variant activity [V, PMID 24403048]. iPSC/organoid HDAC8-CdLS models: an emerging but not yet standard resource.
- **Model databases:** MGI (mouse *Hdac8*), IMPC, ZFIN (zebrafish), Alliance of Genome Resources.

---

## Summary Answer
Cornelia de Lange syndrome 5 is the **X-linked (Xq13.1) form of CdLS caused by loss-of-function variants in *HDAC8***, the deacetylase for the cohesin subunit SMC3. Impaired SMC3 deacetylation disrupts the cohesin acetylation/recycling cycle and cohesin-dependent transcriptional regulation during development (a "cohesinopathy"/disorder of transcriptional regulation), producing a multisystem malformation and neurodevelopmental syndrome that overlaps classic CdLS but is often **milder/atypical**, with discriminating features (delayed fontanelle closure, ocular hypertelorism, dental anomalies); **hemizygous males are more severely affected**, while heterozygous females are variably affected depending on X-inactivation. Management is multidisciplinary and supportive with no disease-modifying therapy; diagnosis rests on consensus clinical criteria plus molecular testing (with episignature/functional assays as adjuncts).

## Key Limitations
- Many phenotype frequencies and prognosis/QoL data are **CdLS-spectrum-level**, not HDAC8-specific (small N for CdLS5).
- No CdLS5-specific survival, incidence, or clinical-trial data; therapeutics remain supportive.
- Variant-level ClinVar/gnomAD counts were not directly queried in this literature-based synthesis and should be verified in those databases for KB population.

## Primary References (PMIDs)
22885700 (Deardorff 2012, *Nature*, HDAC8=SMC3 deacetylase/mechanism); 24403048 (Kaiser 2014, 38-patient HDAC8 cohort, X-linked, discriminating features); 26671848 (Parenti 2016, HDAC8 spectrum, skewed XCI, maternal mosaicism); 19605684 (Haberland 2009, *Hdac8* mouse skull/neural crest, Otx2/Lhx1); 29995837 (Kline 2018, first international consensus); 37377026 (Kaur 2023, 716 probands, DTR framing); 30614194 (Dowsett 2019, diverse populations); 30158690 (Yuan 2019, mild end of spectrum); 27125329 (Kaur 2016, NIPBL levels/severity); 23937369, 36199025, 29536582, 30941551, 40878447 (CdLS neurobehavioral phenotype); 38751117, 37872275 (episignature diagnostics); 31721174 (chromatinopathies review); 29084713 (zebrafish cohesinopathy model).


## Artifacts

- [OpenScientist final report](Cornelia_de_Lange_Syndrome_5-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Cornelia_de_Lange_Syndrome_5-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 18 |
| Resolved | 18 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 18 |
| On topic | 9 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 51 |
| Resolved | 48 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 1 |
| Unverifiable | 2 |
| Terms whose name was checked | 8 |
| Terms named correctly | 0 |
| Terms named as a **different** term | 7 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0000574` (1 mention) - the report calls it "characteristic across CdLS"; HP calls it **Thick eyebrow**
- `HP:0000463` (1 mention) - the report calls it "PMID 30614194"; HP calls it **Anteverted nares**
- `HP:0000219` (1 mention) - the report calls it "PMID 30614194"; HP calls it **Thin upper lip vermilion**
- `HP:0000252` (1 mention) - the report calls it "PMID 30614194"; HP calls it **Microcephaly**
- `HP:0000717` (1 mention) - the report calls it "significantly elevated vs comparison syndromes"; HP calls it **Autism**
- `HP:0000739` (1 mention) - the report calls it "common, persistent; intolerance of uncertainty a driver"; HP calls it **Anxiety**
- `HP:0001250` (1 mention) - the report calls it "subset"; HP calls it **Seizure**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0016575` (obsolete histone deacetylation) (1 mention)

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0001476` (1 mention) - the report calls it "HDAC8-discriminating:** delayed anterior fontanelle closure"; HP calls it **Delayed closure of the anterior fontanelle**, and lists "Delayed closure of anterior fontanelle" among its other names

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.